Non-ionizing Metabolic Imaging for predicting the effect of and guiding Therapeutic Interventions ("MITI")

MITI将开发和成熟一种新颖的、突破性的高精度非电离代谢成像技术，能够快速、无创地检测代谢过程的标志物，例如，细胞增殖和能量代谢。利用代谢成像的结果，医学专家将能够确定治疗的有效性，并比现有技术更快地确定特定疾病。这将增加患者的福祉，降低医疗保健成本，因为不成功的治疗可以停止，并更早地被更有效的（个性化）治疗所取代。该解决方案面向全球数百万患者的巨大市场。MITI建立在NICI的结果基础上，NICI成功发现了在MRI平台上进行代谢成像的基本关键标记分子（1H，2 H，31 P和23 Na），包括通过在7 T MRI平台上插入检测这些分子的能力。MITI包括：进一步开发和测试基本的双调谐代谢成像装置（检测1H和以下分子之一：2 H或31 P或23 Na）。2.验证在特定用例中检测代谢标志物的基本技术：-肺肿瘤和胰腺癌肝转移治疗后的细胞增殖代谢; -心脏药物机制; -肌肉营养不良的能量代谢。3.开发一种先进的四重调谐代谢成像装置，该装置将扩大可以成功并行观察的代谢过程的范围。用例的结果将用于MITI后进行的临床试验的功效计算。MITI合作伙伴的目标是将该技术商业化，在MITI之后直接将其提供给研究中心的临床医生，并在MITI之后3年内将其提供给普通医疗中心

MITI will develop and mature a novel, ground-breaking technology for high precision non-ionizing metabolic imaging, enabling fast and non-invasive detection of the markers of metabolic processes e.g., cell proliferation and energy metabolism. Using the results of metabolic imaging, medical specialists will be able to establish the effectiveness of therapies and determine the specific disease months sooner than is possible with currently available technologies. This will increase patient well-being and reduce the costs of healthcare as unsuccessful therapies can be stopped and replaced earlier by more effective (personalised) therapies. This solution addresses an enormous market with millions of patients worldwide. MITI builds on the results of NICI in which the basic key marker molecules for metabolic imaging on MRI platforms were successfully discovered (1H, 2H, 31P and 23Na), including the capability to detect these by inserts on 7T MRI platforms. MITI comprises: 1. The further development and testing of a basic double tuned metabolic imaging set (detecting 1H and one of the following molecules: 2H or 31P or 23Na). 2. Validation of the basic technology to detect metabolic markers in specific use cases: - cell proliferation metabolism after treatment of lung tumours and pancreatic cancer with liver metastases; - cardiac drug mechanisms; - energy metabolism of muscle dystrophy. 3. Development of an advanced quadruple tuned metabolic imaging set that will broaden the spectrum of metabolic processes that can be successfully viewed in parallel. The results of the use cases will be used for power calculations for clinical trials to be conducted after MITI. The MITI partners aim to commercialize the technology, directly after MITI by providing it to clinicians in research centres and within 3 years after MITI to general medical centres